Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC22A12 | Q96S37 | 2/20 | 0.52 |
| ▸ | CPT1A | P50416 | 6/20 | 0.50 |
| ▸ | CPT1B | Q92523 | 6/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | CPT2 | P23786 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | RORC | P51449 | 4/20 | 0.42 |
| ▸ | NR1I2 | O75469 | 2/20 | 0.42 |
| ▸ | RORA | P35398 | 2/20 | 0.42 |
| ▸ | NR1H2 | P55055 | 2/20 | 0.42 |
| ▸ | NR1H3 | Q13133 | 2/20 | 0.42 |
| ▸ | RORB | Q92753 | 2/20 | 0.42 |
| ▸ | NR1H4 | Q96RI1 | 2/20 | 0.42 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3096475 | 0.89 | CPT1A (0.44) | SLC22A12CPT1ACPT1BL3MBTL1CPT2 | |
| SCHEMBL3083915 | 0.88 | CPT1A (0.50) | SLC22A12CPT1ACPT1BL3MBTL1CPT2 | |
| SCHEMBL3088253 | 0.81 | CPT1A (0.55) | SLC22A12CPT1ACPT1BL3MBTL1CPT2 | |
| SCHEMBL13151422 | 0.79 | CYP2C9 (0.41) | RORC | |
| SCHEMBL3096251 | 0.78 | ITGB3 (0.40) | MEN1KMT2ARORC | |
| SCHEMBL3089857 | 0.78 | CPT1A (0.44) | CPT1ACPT1BL3MBTL1CPT2MEN1 | |
| SCHEMBL3084305 | 0.76 | CPT1A (0.49) | SLC22A12CPT1ACPT1BCPT2MEN1 | |
| SCHEMBL3084581 | 0.74 | CPT1A (0.51) | SLC22A12CPT1ACPT1BL3MBTL1CPT2 | |
| SCHEMBL3082913 | 0.73 | CPT1A (0.49) | SLC22A12CPT1ACPT1BCPT2MEN1 | |
| SCHEMBL3096392 | 0.72 | CPT1A (0.55) | CPT1ACPT1BCPT2RORC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2393812-B1 | SUBSTITUTED SPIROAMIDES AS B1R-MODULATORS | GRUENENTHAL GMBH (DE) | 2013-07-03 | — | — | EP | disclosed |
| US-8357717-B2 | Spiro group-containing amide compounds having bradykinin 1 receptor (B1R) activity | GRUENENTHAL GMBH (DE) | 2013-01-22 | — | — | US | disclosed |
| US-8357717-B2 | Spiro group-containing amide compounds having bradykinin 1 receptor (B1R) activity | GRUENENTHAL GMBH (DE) | 2013-01-22 | — | — | US | disclosed |
| US-8357717-B2 | Spiro group-containing amide compounds having bradykinin 1 receptor (B1R) activity | GRUENENTHAL GMBH (DE) | 2013-01-22 | — | — | US | disclosed |
| US-20100234340-A1 | Substituted Spiroamide Compounds | GRUENENTHAL GMBH (DE) | 2010-09-16 | — | — | US | disclosed |
| US-20100234340-A1 | Substituted Spiroamide Compounds | GRUENENTHAL GMBH (DE) | 2010-09-16 | — | — | US | disclosed |
| US-20100234340-A1 | Substituted Spiroamide Compounds | GRUENENTHAL GMBH (DE) | 2010-09-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100234340-A1 | Substituted Spiroamide Compounds | BDKRB1, BDKRB2, AVPR1B | SLC22A12 2644/4885CPT1A 4096/4885CPT1B 2820/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.